Boston Scientific Corporation (NYSE: BSX) wrapped up a holiday-shortened Christmas Eve session with a modest move in regular trading — and a small uptick in after-hours. With U.S. markets closed on Christmas Day (Dec. 25) and set to reopen Friday (Dec. 26), investors now have a narrow window to digest today’s commentary and position for the next full session. [1]
Below is what happened after the bell on Dec. 24, 2025, what today’s newest analyses are emphasizing, and the practical checklist to keep in mind before trading resumes.
BSX after the bell: the numbers investors are watching tonight
Boston Scientific ended the session near flat and then ticked higher in extended trading:
- Regular-session close:$96.13 (up $0.04, about +0.04%) [2]
- After-hours price:$96.38 (about +$0.25, roughly +0.26%) [3]
- After-hours volume: about 84.49K shares (thin, as expected on a holiday session) [4]
- Day’s range: roughly $95.55–$96.25 [5]
- 52-week range: about $85.98–$109.50 [6]
- Market cap: roughly $142B (varies slightly by data source) [7]
On price alone, the after-hours move is not a “headline” swing — but the context matters: holiday sessions can exaggerate small prints because liquidity is limited.
Why today’s “after the bell” is different: Christmas Eve had an early close
If BSX looked unusually quiet (and the tape felt thin), it wasn’t your imagination.
- The NYSE and Nasdaq ran an early close at 1:00 p.m. ET on Wednesday, Dec. 24, 2025. [8]
- NYSE notes that on this early-close date, certain NYSE late trading sessions end at 5:00 p.m. ET (shorter than the typical extended-hours window investors may expect). [9]
- The broader market’s participation was also light: the Associated Press reported ~1.8 billion shares traded on the NYSE, roughly a third of a normal day. [10]
In other words: tonight’s after-hours quote is useful, but investors should treat it as a low-liquidity signal, not a definitive “new trend,” unless follow-through appears when markets reopen.
Was there breaking Boston Scientific news today? Not from the company’s newsroom
One reason BSX is moving in small increments tonight: there doesn’t appear to be a fresh, company-issued press release dated Dec. 24 on Boston Scientific’s press release page. The most recent items visible there are from earlier in 2025 (e.g., November and October updates). [11]
So today’s action looks less like a reaction to a single headline — and more like a valuation-and-growth debate playing out in a strong year-end market.
Today’s BSX analysis roundup: what the newest commentary is focusing on
Even without a new press release, BSX still attracted fresh coverage today from multiple market-research and investor-commentary outlets. Here are the notable themes from Dec. 24, 2025.
1) Growth engine spotlight: Endoscopy is being framed as a durable driver
A Zacks analysis published on Nasdaq today put Boston Scientific’s Endoscopy business front and center:
- Zacks writes that in the first nine months of 2025, Endoscopy net sales were about $2.16 billion, around 15% of consolidated sales. [12]
- It characterizes the addressable endoscopy market at around $8 billion, with ~6% growth across the company’s 2026–2028 long-range plan, and says management aims to outpace market growth while producing accretive margins. [13]
- It also describes roadmap items like a future platform that could introduce enhanced imaging and AI into single-use scopes, and highlights categories such as pancreaticobiliary, endoluminal surgery, endobariatrics, and core GI franchises. [14]
This matters for the stock because the market has typically rewarded BSX when investors believe growth is broad-based (not only cardiology-driven) and supported by repeatable procedure volumes.
2) The “great business, pricey stock” argument gained traction today
A Seeking Alpha piece published today summed up a view that many long-only investors recognize:
- It argues Boston Scientific continues to deliver robust growth, with drivers including Farapulse (pulsed field ablation), Watchman (left atrial appendage closure), interventional therapies, and neuromodulation — but says valuation limits upside even with strong execution. [15]
- The piece also notes management targets 10%+ annual revenue growth and margin leverage, while warning that guidance below an ~11%–12% growth level for 2026 could disappoint investors (as framed by the author). [16]
- Bottom line from that commentary: strong business momentum, but a “Hold” stance driven by valuation concerns. [17]
Whether readers agree or not, it highlights the key tension for BSX into 2026: can fundamentals keep outrunning expectations?
3) A bullish valuation model also circulated today — but it’s model-dependent
A Yahoo Finance-hosted valuation piece posted within the last several hours referenced a “narrative” fair value around the mid-$120s while noting BSX’s close near $96.13, framing the stock as potentially ~24% undervalued under that approach. [18]
Important nuance: that’s not the same as a Wall Street consensus target (and Yahoo pages often aggregate multiple valuation frameworks). Treat it as one lens, not a definitive forecast.
4) Institutional ownership headlines hit the wires today (based on filings)
Two MarketBeat write-ups published today highlighted changes in institutional positions and summarized Street expectations:
- One report said Munro Partners increased its stake by 29.6% in Q3 to ~1.24 million shares (about $121M at the time of reporting), with BSX becoming a meaningful portfolio position. [19]
- Another said Exchange Traded Concepts LLC boosted its stake in Q3 and reiterated that institutions own a large share of the float, while also summarizing a “consensus” Buy stance and price targets. [20]
The key takeaway: institutional ownership remains high — but remember these stories are built on historical filings, meaning they can describe positioning with a time lag.
Fundamentals refresher: the last major company update still anchors expectations
To understand what the market is “pricing,” it helps to recall Boston Scientific’s most recent major earnings guidance updates.
Reuters reported after Boston Scientific’s third-quarter results that the company delivered adjusted EPS of $0.75 (above estimates cited by Reuters) and revenue of $5.07B, and raised full-year adjusted EPS guidance to about $3.02–$3.04, with Q4 EPS guidance of $0.77–$0.79. [21]
Reuters also noted the company’s plan to acquire the remaining equity in Nalu Medical for roughly $533 million, a deal positioned to bolster its chronic pain/neuromodulation offerings. [22]
Those guideposts are still central because they frame the near-term question investors will ask when BSX reports again: Is the company tracking above, in line, or below those targets?
Forecasts into 2026: where analysts (and aggregators) place BSX
For “what to know before the next open,” investors typically check consensus targets and the next catalyst date.
- Investing.com shows an average 12‑month price target around $125.86, with a high estimate of $140 and a low estimate of $99, and also lists BSX with a Strong Buy-style consensus in its compiled analyst data. [23]
- MarketBeat’s consensus snapshot is similar: a consensus price target around $124.85, with a high target of $140 (its low differs by provider). [24]
- Investing.com also lists the next earnings report date as Feb. 4, 2026 (a key “next checkpoint” for the story). [25]
The big picture from these snapshots: many analysts still see meaningful upside versus the mid‑$90s price area — but the market is simultaneously debating whether that upside is already partly “earned” by the stock’s premium valuation versus some medtech peers (a point raised in multiple commentaries).
What to know before the market opens “tomorrow” (and the calendar reality)
Because this request references “tomorrow,” it’s worth stating clearly:
- U.S. markets are closed Thursday, Dec. 25, 2025 (Christmas Day). [26]
- Markets reopen Friday, Dec. 26 for a full session, though year-end volumes often remain light. [27]
So the practical “before the bell” preparation is really about Friday’s open.
Pre-open checklist for BSX before trading resumes Friday, Dec. 26
1) Don’t overread holiday after-hours prints
BSX’s after-hours move is small, and extended trading today occurred in a market environment where liquidity is unusually thin. That can create clean-looking price moves that don’t always hold once full volume returns. [28]
2) Keep an eye on the medtech “competitive tape”
Zacks’ piece didn’t just discuss BSX; it also referenced peer momentum and regulatory developments in adjacent areas (for example, updates involving Abbott and Edwards Lifesciences). Those competitive reads can influence sector sentiment even if they’re not directly about Boston Scientific. [29]
3) Watch the market mood — it’s a record-setting tape
The broader market finished Christmas Eve higher and near records, with the S&P 500 closing at 6,932.05 and the Dow and Nasdaq also up, according to AP. A strong risk-on mood can support high-quality healthcare growth names, but any abrupt shift in rates or macro expectations can still pressure valuation-sensitive stocks. [30]
4) Know the next “hard” catalyst date
If you’re trying to filter signal from noise, earnings dates matter more than day-to-day commentary. Investing.com lists Boston Scientific’s next earnings release on Feb. 4, 2026. [31]
5) Map the “expectations range” that Friday’s market will trade against
With BSX around $96 and many published targets clustering in the mid‑$120s (depending on provider), the near-term push-pull becomes:
- Can growth drivers (like Farapulse/Watchman and segments such as Endoscopy) keep surprising to the upside? [32]
- Or does valuation cap near-term upside until the next earnings checkpoint? [33]
That framing helps explain why BSX can be “quiet” on a day without fresh corporate news — and still be heavily discussed in analyst and investor circles.
Bottom line: BSX ends Christmas Eve steady, but the debate is heating up
Boston Scientific stock finishes Dec. 24, 2025 close to flat in regular trading and slightly higher after hours — a muted move that fits a holiday tape. [34]
The more important story tonight isn’t a dramatic price spike; it’s the narrative battle:
- Bulls point to durable procedure-driven growth across segments (including Endoscopy) and a steady pipeline. [35]
- Skeptics don’t necessarily dispute the operational strength — they question how much of that strength is already priced in. [36]
With markets closed Dec. 25 and reopening Dec. 26, the next “true” read will come when normal liquidity returns — and when investors recalibrate positions for the first full sessions of the final week of the year. [37]
References
1. apnews.com, 2. www.marketwatch.com, 3. www.marketwatch.com, 4. www.marketwatch.com, 5. www.investing.com, 6. www.investing.com, 7. www.investing.com, 8. www.nyse.com, 9. www.nyse.com, 10. apnews.com, 11. news.bostonscientific.com, 12. www.nasdaq.com, 13. www.nasdaq.com, 14. www.nasdaq.com, 15. seekingalpha.com, 16. seekingalpha.com, 17. seekingalpha.com, 18. finance.yahoo.com, 19. www.marketbeat.com, 20. www.marketbeat.com, 21. www.reuters.com, 22. www.reuters.com, 23. www.investing.com, 24. www.marketbeat.com, 25. www.investing.com, 26. www.nasdaq.com, 27. apnews.com, 28. apnews.com, 29. www.nasdaq.com, 30. apnews.com, 31. www.investing.com, 32. seekingalpha.com, 33. seekingalpha.com, 34. www.marketwatch.com, 35. www.nasdaq.com, 36. seekingalpha.com, 37. apnews.com
